Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1-9. (Cancelled)

10. (Currently Amended) A method for treatment of asthma, chronic obstructive pulmonary disease (COPD), premature labor in midwifery (tocolysis), atrioventricular block, bradycardic heart rhythm disorders, cardiovascular shock, or itching and irritation of the skin in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1



1

wherein:

R^1 is C_1-C_4-alkyl;

R^2 is C_1-C_4-alkyl; and

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono- or polysubstituted, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid ~~according to one of claims 1 to 7~~.

11. (Currently Amended) A pharmaceutical composition comprising:

(a) ~~the~~ a compound of formula **1**



1

wherein:

R^1 is C_1-C_4-alkyl;

R^2 is C_1-C_4-alkyl; and

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono- or polysubstituted, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.
~~according to one of claims 1 to 7~~; and

(b) at least one other active substance selected from anticholinergics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.

12. (Original) The pharmaceutical composition of claim 11, further comprising a physiologically acceptable excipient.

13. (Currently Amended) A pharmaceutical composition comprising:

(a) ~~the~~ a compound of formula **1**



1

wherein:
R^1 is C_1-C_4-alkyl;
R^2 is C_1-C_4-alkyl; and
R^3 is C_1-C_4-alkyl or phenyl, each optionally mono- or polysubstituted, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.
~~according to one of claims 1 to 7~~; and

(b) tiotropium bromide.

14. (Original) The pharmaceutical composition of claim 13, further comprising a physiologically acceptable excipient.

15. (Currently Amended) A pharmaceutical composition comprising:

(a) ~~the~~ a compound of formula **1**



1

wherein:

R^1 is C_1-C_4-alkyl;

R^2 is C_1-C_4-alkyl; and

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono- or polysubstituted, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

~~according to one of claims 1 to 7~~;

(b) tiotropium bromide; and

(c) at least one other active substance selected from anticholinergics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.

16. (Original) The pharmaceutical composition of claim 13, further comprising a physiologically acceptable excipient.

17. (New) The method according to claim 10 comprising administering to the patient in need thereof an effective amount of the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from C_1-C_3-alkyl, CF_3, methoxy, ethoxy, hydroxy, fluorine, chlorine, bromine, $-OCF_3$, $-CHF_2$, $-NHCOCH_3$, and $-NHSO_2CH_3$, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

18. (New) A method according to claim 10 comprising administering to the patient in need thereof an effective amount of the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, ethyl, CF_3, methoxy, ethoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

19. (New) A method according to claim 10 comprising administering to the patient in need thereof an effective amount of the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

20. (New) A method according to claim 10 comprising administering to the patient in need thereof an effective amount of the compound of general formula **1**



1

wherein:

R^1 is methyl or ethyl;

R^2 is methyl; and

R^3 is methyl, ethyl, or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

21. (New). A method according to claim 10 comprising administering to the patient in need thereof an effective amount of the compound of general formula **1**



1

wherein:
R^1 is methyl;
R^2 is methyl; and
R^3 is methyl or phenyl, each optionally mono-, di-, or trisubstituted by one or more groups selected from methyl, ethyl, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

22. (New) A method according to claim 10 comprising administering to the patient in need thereof an effective amount of the compound of general formula **1**



1

wherein:
R^1 is methyl;
R^2 is methyl; and
R^3 is methyl or phenyl, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

23. (New) The pharmaceutical composition according to claim 11, comprising the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from C_1-C_3-alkyl, CF_3, methoxy, ethoxy, hydroxy, fluorine, chlorine, bromine, $-OCF_3$, $-CHF_2$, $-NHCOCH_3$, and $-NHSO_2CH_3$, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

24. (New) The pharmaceutical composition according to claim 11, comprising the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, ethyl, CF_3, methoxy, ethoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

25. (New) The pharmaceutical composition according to claim 11, comprising the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

26. (New) The pharmaceutical composition according to claim 11, comprising the compound of general formula **1**



1

wherein:
R^1 is methyl or ethyl;
R^2 is methyl; and
R^3 is methyl, ethyl, or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

27. (New) The pharmaceutical composition according to claim 11, comprising the compound of general formula **1**



1

wherein:
R^1 is methyl;
R^2 is methyl; and
R^3 is methyl or phenyl, each optionally mono-, di-, or trisubstituted by one or more groups selected from methyl, ethyl, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$, or the corresponding acid addition salt with a pharmacologically acceptable acid.

28. (New) The pharmaceutical composition according to claim 11, comprising the compound of general formula **1**



1

wherein:

R^1 is methyl;

R^2 is methyl; and

R^3 is methyl or phenyl, or R^2 and R^3 together are $-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

29. (New) The pharmaceutical composition according to claim 13, comprising the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from C_1-C_3-alkyl, CF_3, methoxy, ethoxy, hydroxy, fluorine, chlorine, bromine, $-OCF_3$, $-CHF_2$, $-NHCOCH_3$, and $-NHSO_2CH_3$, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

30. (New) The pharmaceutical composition according to claim 13, comprising the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, ethyl, CF_3, methoxy, ethoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

31. (New) The pharmaceutical composition according to claim 13, comprising the compound of general formula **1**



1

wherein:
R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

32. (New) The pharmaceutical composition according to claim 13, comprising the compound of general formula **1**



1

wherein:
R^1 is methyl or ethyl;
R^2 is methyl; and
R^3 is methyl, ethyl, or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

33. (New) The pharmaceutical composition according to claim 13, comprising the compound of general formula **1**



1

wherein:

R^1 is methyl;

R^2 is methyl; and

R^3 is methyl or phenyl, each optionally mono-, di-, or trisubstituted by one or more groups selected from methyl, ethyl, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$, or the corresponding acid addition salt with a pharmacologically acceptable acid.

34. (New) The pharmaceutical composition according to claim 13, comprising the compound of general formula **1**



1

wherein:

R^1 is methyl;

R^2 is methyl; and

R^3 is methyl or phenyl, or R^2 and R^3 together are $-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

35. (New) The pharmaceutical composition according to claim 15, comprising the compound of general formula **1**



1

wherein:

R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from C_1-C_3-alkyl, CF_3, methoxy, ethoxy, hydroxy, fluorine,

chlorine, bromine, $-OCF_3$, $-CHF_2$, $-NHCOCH_3$, and $-NHSO_2CH_3$, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

36. (New) The pharmaceutical composition according to claim 15, comprising the compound of general formula **1**



1

wherein:
R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, ethyl, CF_3, methoxy, ethoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$ or $-CH_2-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

37. (New) The pharmaceutical composition according to claim 15, comprising the compound of general formula **1**



1

wherein:
R^3 is C_1-C_4-alkyl or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,
or the corresponding acid addition salt with a pharmacologically acceptable acid.

38. (New) The pharmaceutical composition according to claim 15, comprising the compound of general formula **1**



1

wherein:

R^1 is methyl or ethyl;

R^2 is methyl; and

R^3 is methyl, ethyl, or phenyl, each optionally mono-, di-, tri-, or tetrasubstituted by one or more groups selected from methyl, CF_3, methoxy, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.

39. (New) The pharmaceutical composition according to claim 15, comprising the compound of general formula **1**



1

wherein:

R^1 is methyl;

R^2 is methyl; and

R^3 is methyl or phenyl, each optionally mono-, di-, or trisubstituted by one or more groups selected from methyl, ethyl, and hydroxy, or R^2 and R^3 together are $-CH_2-CH_2-$, or the corresponding acid addition salt with a pharmacologically acceptable acid.

40. (New) The pharmaceutical composition according to claim 15, comprising the compound of general formula **1**



1

wherein:

R^1 is methyl;

R^2 is methyl; and

R^3 is methyl or phenyl, or R^2 and R^3 together are $-CH_2-CH_2-$,

or the corresponding acid addition salt with a pharmacologically acceptable acid.